A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation.

Trial Profile

A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ARISTOTLE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Jul 2017 Results of post-hoc analysis published in the American Journal of Medicine
    • 10 Jun 2017 Biomarkers information updated
    • 06 Mar 2017 Post-hoc analyses will be presented at the American College of Cardiology (ACC) 66th Annual Scientific Session 2017, according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top